Opposing roles of PGD₂ in GBM

Area of Science:

• Neuro-oncology
• Cancer Biology
• Lipid Signaling

Background:

• Glioblastoma (GBM) remains a challenging malignancy despite advances in treatment.
• The role of bioactive lipids, specifically Prostaglandin D2 (PGD2), in GBM is not well understood.
• GBM cells produce various bioactive lipids that influence tumor progression.

Purpose of the Study:

• To investigate the impact of Prostaglandin D2 (PGD2) on glioblastoma (GBM) cell activities in vitro.
• To determine the concentration-dependent effects of PGD2 on GBM cell proliferation, apoptosis, mitosis, and migration.
• To analyze PGD2 levels in different grades of gliomas.

Main Methods:

• RT-PCR, immunohistochemistry, and HPLC-MS/MS were used to detect the PGD2 synthesis pathway in GBM cell lines.
• GBM cells were treated with varying concentrations of PGD2 to assess effects on cell count, apoptosis, mitosis, and migration.
• HPLC-MS/MS was employed to compare PGD2 lipid composition in Grade II/III gliomas versus GBM.

Main Results:

• Endogenous PGD2 and its associated enzymes/receptors were identified in GBM cells.
• Exogenous PGD2 demonstrated a concentration-dependent effect on cell count, increasing it at low concentrations (<1μM) and decreasing it at high concentrations (10μM).
• A significant increase in PGD2 levels was observed from Grade II/III gliomas to GBM, suggesting a pro-tumorigenic role.

Conclusions:

• Prostaglandin D2 exhibits dynamic, concentration-dependent effects on GBM cell behavior.
• Elevated PGD2 production in GBM correlates with increased glioma growth and invasion.
• Further investigation into prostaglandin signaling pathways in GBM is crucial for developing novel therapeutic strategies.